ArticleOpen veterinary journal2026
Canine parvovirus type 2 antigenic variants and in-hospital mortality in central Spain: Retrospective and prospective data (2003-2014).
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Canine parvovirus type 2 (CPV-2) remains a major cause of morbidity and mortality in young dogs. Clinical and molecular data obtained between 2003 and 2014 from a veterinary teaching hospital in central Spain were analyzed to characterize circulating CPV-2 antigenic variants and associated in-hospital outcomes. As the samples were collected more than a decade ago, the reported frequencies represent historical CPV-2 data rather than the current circulation. Aim: This study aimed to describe the historical distribution of CPV-2 antigenic variants (2a, 2b, and 2c) detected in hospital-presenting clinical samples collected between 2003 and 2014, document rare detections of feline panleukopenia virus (FPV) and the Cornell vaccine strain, and analyze clinical variables associated with in-hospital mortality. Methods: A retrospective series of 110 clinical samples were analysed using rapid antigen tests and polymerase chain reaction. Adequate amplification yielded 583-bp VP2 fragments, of which 50 were selected for sequencing (42 produced high-quality reads). Species identification (CPV-2 vs. FPV) was based on full-length amplicon alignment and phylogenetic clustering. Amino acid residue 426 was used as a supporting marker to distinguish the CPV-2a, CPV-2b, and CPV-2c antigenic variants. Logistic regression models estimated odds ratios (OR) with 95% confidence intervals (CI). Results: In the sequenced archival cases, CPV-2c was the predominant variant (42.9%, 18/42), followed by CPV-2a (31.0%, 13/42), the Cornell vaccine strain (11.9%, 5/42), CPV-2b (9.5%, 4/42), and FPV (4.8%, 2/42). Small-breed dogs (<15 kg) exhibited higher odds of in-hospital death (OR = 2.74; 95% CI = 1.18-6.37). Dogs presenting with gastrointestinal signs in combination with neurological and/or respiratory signs had markedly increased odds of mortality (OR = 9.14; 95% CI = 2.29-36.40). No statistically significant associations were observed between mortality and antigenic variant or vaccination status. Conclusion: This archival cohort provides a historical reference for CPV epidemiology in central Spain. CPV-2c was the most common variant. Breed size and multisystemic involvement were significantly associated with in-hospital mortality. However, contemporary sequencing would be necessary to monitor the evolution of CPV-2 beyond the study period due to the historical nature of the study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.